<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Qiagen Nv — News on 6ix</title>
<link>https://6ix.com/company/qiagen-nv</link>
<description>Latest news and press releases for Qiagen Nv on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 20:16:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/qiagen-nv" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835b3f778dffbe2df112e87.webp</url>
<title>Qiagen Nv</title>
<link>https://6ix.com/company/qiagen-nv</link>
</image>
<item>
<title>QIAGEN reports preliminary Q1 2026 results: achieves adjusted EPS outlook with mixed sales trends; updates full-year 2026 outlook</title>
<link>https://6ix.com/company/qiagen-nv/news/qiagen-reports-preliminary-q1-2026-results-achieves-adjusted-eps-outlook-with-mixed-sales-trends-updates-full-year-2026-outlook</link>
<guid isPermaLink="true">https://6ix.com/company/qiagen-nv/news/qiagen-reports-preliminary-q1-2026-results-achieves-adjusted-eps-outlook-with-mixed-sales-trends-updates-full-year-2026-outlook</guid>
<pubDate>Mon, 27 Apr 2026 20:16:00 GMT</pubDate>
<description>VENLO, the Netherlands, April 27, 2026--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary results for the first quarter of 2026, continuing to deliver strong profitability as adjusted diluted earnings per share (EPS) achieved the outlook. Sales trends were mixed, as lower QuantiFERON sales and cautious U.S. Life Sciences customer demand offset solid growth in other areas of the portfolio.</description>
</item>
<item>
<title>QIAGEN to Showcase New Sample to Insight Solutions for Complex Oncology Applications at AACR 2026</title>
<link>https://6ix.com/company/qiagen-nv/news/qiagen-to-showcase-new-sample-to-insight-solutions-for-complex-oncology-applications-at-aacr-2026</link>
<guid isPermaLink="true">https://6ix.com/company/qiagen-nv/news/qiagen-to-showcase-new-sample-to-insight-solutions-for-complex-oncology-applications-at-aacr-2026</guid>
<pubDate>Thu, 16 Apr 2026 20:05:00 GMT</pubDate>
<description>GERMANTOWN, Md. & VENLO, Netherlands, April 16, 2026--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it will showcase its oncology workflow applications at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, demonstrating how its portfolio connects sample preparation with multi-omics profiling and genomic data interpretation to support cancer research and molecular diagnostics.</description>
</item>
<item>
<title>QIAGEN Expands Into Bloodstream Infection Syndromic Testing With New Rapid QIAstat-Dx Panel</title>
<link>https://6ix.com/company/qiagen-nv/news/qiagen-expands-into-bloodstream-infection-syndromic-testing-with-new-rapid-qiastat-dx-panel</link>
<guid isPermaLink="true">https://6ix.com/company/qiagen-nv/news/qiagen-expands-into-bloodstream-infection-syndromic-testing-with-new-rapid-qiastat-dx-panel</guid>
<pubDate>Tue, 14 Apr 2026 20:05:00 GMT</pubDate>
<description>HILDEN, Germany & VENLO, Netherlands, April 14, 2026--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its expansion into syndromic testing for bloodstream infections with the launch of the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel.</description>
</item>
<item>
<title>Parse Biosciences, a QIAGEN Company, Launches FFPE-compatible Barcoding Technology for Whole Transcriptome Single Cell Analysis</title>
<link>https://6ix.com/company/qiagen-nv/news/parse-biosciences-a-qiagen-company-launches-ffpe-compatible-barcoding-technology-for-whole-transcriptome-single-cell-analysis</link>
<guid isPermaLink="true">https://6ix.com/company/qiagen-nv/news/parse-biosciences-a-qiagen-company-launches-ffpe-compatible-barcoding-technology-for-whole-transcriptome-single-cell-analysis</guid>
<pubDate>Tue, 31 Mar 2026 16:40:00 GMT</pubDate>
<description>SEATTLE, March 31, 2026--Parse Biosciences, a QIAGEN company and the leading provider of scalable and accessible single-cell sequencing solutions, today announced the commercial availability of Evercode™ Whole Transcriptome FFPE kits that are now shipping to customers.</description>
</item>
<item>
<title>Qiagen Announces Form 20-F Annual Report Filing for 2025 Results</title>
<link>https://6ix.com/company/qiagen-nv/news/qiagen-announces-form-20-f-annual-report-filing-for-2025-results</link>
<guid isPermaLink="true">https://6ix.com/company/qiagen-nv/news/qiagen-announces-form-20-f-annual-report-filing-for-2025-results</guid>
<pubDate>Fri, 20 Mar 2026 11:30:00 GMT</pubDate>
<description>VENLO, the Netherlands, March 20, 2026--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN’s website here.</description>
</item>
<item>
<title>QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention</title>
<link>https://6ix.com/company/qiagen-nv/news/qiagen-highlights-newly-published-data-supporting-efficacy-of-quantiferon-for-tb-prevention</link>
<guid isPermaLink="true">https://6ix.com/company/qiagen-nv/news/qiagen-highlights-newly-published-data-supporting-efficacy-of-quantiferon-for-tb-prevention</guid>
<pubDate>Thu, 19 Mar 2026 20:05:00 GMT</pubDate>
<description>GERMANTOWN, Md. & VENLO, Netherlands, March 19, 2026--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced newly published clinical and health economic data supporting the use of its QuantiFERON-TB Gold Plus (QFT-Plus) blood test for detecting tuberculosis (TB) infection, particularly in immunocompromised and other high-risk populations.</description>
</item>
<item>
<title>QIAGEN Receives U.S. Clearance for Gastrointestinal Panels on Fully Automated QIAstat-Dx Rise Syndromic Testing System</title>
<link>https://6ix.com/company/qiagen-nv/news/qiagen-receives-us-clearance-for-gastrointestinal-panels-on-fully-automated-qiastat-dx-rise-syndromic-testing-system</link>
<guid isPermaLink="true">https://6ix.com/company/qiagen-nv/news/qiagen-receives-us-clearance-for-gastrointestinal-panels-on-fully-automated-qiastat-dx-rise-syndromic-testing-system</guid>
<pubDate>Tue, 10 Mar 2026 21:05:00 GMT</pubDate>
<description>GERMANTOWN, Md. & VENLO, Netherlands, March 10, 2026--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the use of all QIAstat-Dx® Gastrointestinal (GI) Panels on the QIAstat-Dx Rise automated syndromic testing system.</description>
</item>
<item>
<title>Parse Biosciences Launches Evercode Whole Transcriptome V4 With Shorter Workflow, Higher Sensitivity and Higher Cell Recovery</title>
<link>https://6ix.com/company/qiagen-nv/news/parse-biosciences-launches-evercode-whole-transcriptome-v4-with-shorter-workflow-higher-sensitivity-and-higher-cell-recovery</link>
<guid isPermaLink="true">https://6ix.com/company/qiagen-nv/news/parse-biosciences-launches-evercode-whole-transcriptome-v4-with-shorter-workflow-higher-sensitivity-and-higher-cell-recovery</guid>
<pubDate>Thu, 19 Feb 2026 13:00:00 GMT</pubDate>
<description>SEATTLE, Wash. & VENLO, the Netherlands, February 19, 2026--Parse Biosciences, a QIAGEN company (NYSE: QGEN, Frankfurt Prime Standard: QIA), and the leading provider of scalable and accessible single-cell sequencing solutions today announced the launch of the new Evercode™ Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing.</description>
</item>
<item>
<title>QIAGEN Exceeds Q4 2025 Outlook Driven by Growth Pillars</title>
<link>https://6ix.com/company/qiagen-nv/news/qiagen-exceeds-q4-2025-outlook-210500626</link>
<guid isPermaLink="true">https://6ix.com/company/qiagen-nv/news/qiagen-exceeds-q4-2025-outlook-210500626</guid>
<pubDate>Wed, 04 Feb 2026 21:05:00 GMT</pubDate>
<description>VENLO, Netherlands, February 04, 2026--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced results for the fourth quarter and full-year 2025.</description>
</item>
<item>
<title>QIAGEN Showcases QIAsprint Connect High-Throughput Automation System for Labs Worldwide at SLAS 2026</title>
<link>https://6ix.com/company/qiagen-nv/news/qiagen-showcases-qiasprint-connect-high-210500265</link>
<guid isPermaLink="true">https://6ix.com/company/qiagen-nv/news/qiagen-showcases-qiasprint-connect-high-210500265</guid>
<pubDate>Tue, 03 Feb 2026 21:05:00 GMT</pubDate>
<description>GERMANTOWN, Md. & VENLO, Netherlands, February 03, 2026--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the first public showcase of QIAsprint Connect at SLAS 2026 in Boston, marking QIAGEN’s entry into high-throughput benchtop automation for sample processing in research laboratories.</description>
</item>
<item>
<title>QIAGEN Appoints Mark Stevenson to Supervisory Board</title>
<link>https://6ix.com/company/qiagen-nv/news/qiagen-appoints-mark-stevenson-supervisory-210500728</link>
<guid isPermaLink="true">https://6ix.com/company/qiagen-nv/news/qiagen-appoints-mark-stevenson-supervisory-210500728</guid>
<pubDate>Mon, 26 Jan 2026 21:05:00 GMT</pubDate>
<description>VENLO, Netherlands, January 26, 2026--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Mark Stevenson has been appointed as an independent member of the Supervisory Board as of January 23, 2026, and will stand for election at the next Annual General Meeting in June 2026.</description>
</item>
<item>
<title>QIAGEN N.V. to Release Results for Q4 2025 and Hold Webcast</title>
<link>https://6ix.com/company/qiagen-nv/news/qiagen-n-v-release-results-145600832</link>
<guid isPermaLink="true">https://6ix.com/company/qiagen-nv/news/qiagen-n-v-release-results-145600832</guid>
<pubDate>Mon, 19 Jan 2026 14:56:00 GMT</pubDate>
<description>VENLO, Netherlands, January 19, 2026--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the fourth quarter of 2025.</description>
</item>
<item>
<title>QIAGEN Sets 2026 Priorities to Drive Growth Across Five Pillars Toward Achieving 2028 Goals for Solid Profitable Growth</title>
<link>https://6ix.com/company/qiagen-nv/news/qiagen-sets-2026-priorities-drive-070000040</link>
<guid isPermaLink="true">https://6ix.com/company/qiagen-nv/news/qiagen-sets-2026-priorities-drive-070000040</guid>
<pubDate>Mon, 12 Jan 2026 07:00:00 GMT</pubDate>
<description>VENLO, Netherlands, January 12, 2026--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its 2026 priorities across its five growth pillars focused on advancing product commercialization, regulatory milestones and automation system innovations to support its goal for $2 billion of combined annual pillar sales in 2028.</description>
</item>
<item>
<title>QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million</title>
<link>https://6ix.com/company/qiagen-nv/news/qiagen-announces-details-completion-synthetic-162700862</link>
<guid isPermaLink="true">https://6ix.com/company/qiagen-nv/news/qiagen-announces-details-completion-synthetic-162700862</guid>
<pubDate>Thu, 18 Dec 2025 16:27:00 GMT</pubDate>
<description>VENLO, Netherlands, December 18, 2025--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced details for completion of plans to return approximately $500 million to shareholders through a synthetic share repurchase that combines a direct capital repayment to QIAGEN shareholders with a reverse stock split.</description>
</item>
<item>
<title>QIAGEN Unveils QIAsymphony Connect and Showcases New Precision Oncology Innovations at AMP 2025</title>
<link>https://6ix.com/company/qiagen-nv/news/qiagen-unveils-qiasymphony-connect-showcases-063000164</link>
<guid isPermaLink="true">https://6ix.com/company/qiagen-nv/news/qiagen-unveils-qiasymphony-connect-showcases-063000164</guid>
<pubDate>Mon, 10 Nov 2025 06:30:00 GMT</pubDate>
<description>GERMANTOWN, Md. & VENLO, Netherlands, November 10, 2025--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the debut of QIAsymphony Connect, the next generation of QIAGEN’s widely adopted automated nucleic acid purification platform, at the 2025 AMP (Association for Molecular Pathology) annual meeting from November 11-15 in Boston.</description>
</item>
<item>
<title>QIAGEN Exceeds Q3 2025 Outlook, Raises FY 2025 Adj. EPS Target, Announces Parse Acquisition and $500 Million Share Repurchase</title>
<link>https://6ix.com/company/qiagen-nv/news/qiagen-exceeds-q3-2025-outlook-180400851</link>
<guid isPermaLink="true">https://6ix.com/company/qiagen-nv/news/qiagen-exceeds-q3-2025-outlook-180400851</guid>
<pubDate>Tue, 04 Nov 2025 18:04:00 GMT</pubDate>
<description>VENLO, Netherlands, November 04, 2025--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced results for the third quarter of 2025 and reaffirmed its outlook for solid profitable growth while raising its profitability targets.</description>
</item>
<item>
<title>QIAGEN to acquire Parse Biosciences, expanding its Sample technologies portfolio into highly scalable single-cell solutions</title>
<link>https://6ix.com/company/qiagen-nv/news/qiagen-acquire-parse-biosciences-expanding-180300190</link>
<guid isPermaLink="true">https://6ix.com/company/qiagen-nv/news/qiagen-acquire-parse-biosciences-expanding-180300190</guid>
<pubDate>Tue, 04 Nov 2025 18:03:00 GMT</pubDate>
<description>VENLO, Netherlands & SEATTLE, November 04, 2025--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has entered into a definitive agreement to fully acquire Parse Biosciences, a leading provider of scalable, instrument-free solutions for single-cell research.</description>
</item>
<item>
<title>QIAGEN Launches New Automated Sexual Assault Sample Processing Kit at ISHI 2025</title>
<link>https://6ix.com/company/qiagen-nv/news/qiagen-launches-automated-sexual-assault-210500937</link>
<guid isPermaLink="true">https://6ix.com/company/qiagen-nv/news/qiagen-launches-automated-sexual-assault-210500937</guid>
<pubDate>Thu, 30 Oct 2025 21:05:00 GMT</pubDate>
<description>GERMANTOWN, Md. & VENLO, Netherlands, October 30, 2025--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the EZ2 DNA Investigator Sep&Prep Kit, a fully automated solution for processing sexual assault samples, at the upcoming International Symposium on Human Identification 2025 (ISHI) from November 3-6 in Palm Beach, Florida.</description>
</item>
<item>
<title>QIAGEN Marks 4,000th QIAcube Connect Placement, Reaffirming Leadership in Automated Sample Processing</title>
<link>https://6ix.com/company/qiagen-nv/news/qiagen-marks-4-000th-qiacube-210500164</link>
<guid isPermaLink="true">https://6ix.com/company/qiagen-nv/news/qiagen-marks-4-000th-qiacube-210500164</guid>
<pubDate>Tue, 28 Oct 2025 21:05:00 GMT</pubDate>
<description>VENLO, Netherlands, & GERMANTOWN, Maryland, October 28, 2025--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the 4,000th placement of its QIAcube Connect instrument, a significant milestone in driving automation adoption for sample processing across life science and diagnostic labs.</description>
</item>
<item>
<title>QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast</title>
<link>https://6ix.com/company/qiagen-nv/news/qiagen-n-v-release-results-122400327</link>
<guid isPermaLink="true">https://6ix.com/company/qiagen-nv/news/qiagen-n-v-release-results-122400327</guid>
<pubDate>Mon, 13 Oct 2025 12:24:00 GMT</pubDate>
<description>VENLO, Netherlands, October 13, 2025--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.</description>
</item>
</channel>
</rss>